Market Overview

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Fusion Pharm, Inc.


Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Fusion Pharm, Inc. (OTC: FSPM) resulting from allegations that Fusion Pharm may have issued materially misleading business information to the investing public.

On September 16, 2016, the SEC announced fraud charges against Fusion Pharm and its CEO, Scott M. Dittman, among others, for misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Fusion Pharm investors. If you purchased shares of Fusion Pharm on or before September 16, 2016, please visit the firm's website at for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at or

Follow us for updates on LinkedIn: or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: 212-686-1060
Toll Free: 866-767-3653
Fax: 212-202-3827

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at